Lannett Gets FDA Approval For Oxycodone Hydrochloride Capsules 5 Mg

(RTTNews) - Lannett Company, Inc. (LCI) Monday said the U.S. Food and Drug Administration or FDA has approved its Abbreviated New Drug Application or ANDA for Oxycodone Hydrochloride Capsules, 5 mg, which is the therapeutic equivalent to the reference listed drug, Oxycodone Hydrochloride Capsules, 5 mg, of Lehigh Valley Technologies, Inc. The company said it expects to begin shipping of the product in the coming months.

According to IMS, total sales of Oxycodone Hydrochloride Capsules, 5 mg, for the year ended June 2014 at Average Wholesale Price (AWP) were nearly $7.1 million.

Arthur Bedrosian, president and chief executive officer of Lannett commented: "Oxycodone Hydrochloride Capsules, 5 mg, represents our third product approved by the FDA thus far in 2014, and, importantly, adds to our goal of vertical integration."